Free Trial
NASDAQ:GHRS

GH Research Q1 2025 Earnings Report

GH Research logo
$10.42 -0.38 (-3.52%)
As of 05/9/2025 03:58 PM Eastern

GH Research EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.61
Beat/Miss
Beat by +$0.42
One Year Ago EPS
N/A

GH Research Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GH Research Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

GH Research Earnings Headlines

Trump’s Bitcoin Reserve is No Accident…
Remember when they said crypto would never go mainstream? Well, something remarkable has happened… BlackRock, the world's largest asset manager, is now buying Bitcoin through ETFs. Fidelity, Goldman Sachs, and Citadel have joined them. We have the most pro-crypto administration in history. And the regulatory barriers are finally falling.
GH Research (GHRS) to Release Earnings on Friday
See More GH Research Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GH Research? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GH Research and other key companies, straight to your email.

About GH Research

GH Research (NASDAQ:GHRS), together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

View GH Research Profile

More Earnings Resources from MarketBeat